secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000950170-22-023214
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q3 2022 net loss $46.1M, cash $758.3M, pipeline advances
----------------------------------------------------------------

- Net loss of $46.1M ($0.56 loss per share); prior-year net income $126.6M ($1.56 EPS).
- Collaboration revenue $14.9M, down from $182.4M YoY due to $173.4M GSK license in 2021.
- Cash, cash equivalents and investments $758.3M; runway through 2024.
- Enrolling Phase 3 INFRONT-3 (latozinemab for FTD-GRN) and Phase 2 INVOKE-2 (AL002 for early AD).
- Initiated Phase 1 for AL044 (MS4A target for Alzheimer’s); IND for AL009 (immuno-oncology) expected Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017022023214/0000950170-22-023214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017022023214/alec-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer